Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 477 participants.

Also called NCT05120193

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 477 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05120193
Other papers using this trial's data
  • Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial Nature medicine, 2024-08 DOI, PubMed 38760584, PMC11333282 In the PMC Open Access subset under CC BY.
  • Impact of linear ablation in persistent atrial fibrillation using a dual-energy, wide-footprint catheter: Analysis from the SPHERE Per-AF randomized trial Heart rhythm, 2026-07 DOI, PubMed 41655663
  • Operator learning curve with a novel dual-energy lattice-tip ablation system Heart rhythm, 2026-01 DOI, PubMed 39922404

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Israel (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05120193. Randomized; single masking; primary purpose treatment. Start 2021-12-14 (actual); primary completion 2024-01-10 (actual). Results posted on 2025-02-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
Acronym
SPHERE Per-AF
Intervention (Device)
Mapping and Ablation
Lead sponsor
Medtronic Cardiac Ablation Solutions (class: industry)

Record details

Record id
cardio:ct-nct05120193
Content hash
8daad0e2017437979a26afc85c71dddc0ed687653421a18a84752f48d5b54bec